Precision Therapeutics announces new tumor profiling product supplement utility ChemoFx ® and further personalize cancer treatment

Precision Therapeutics, Inc. announced that the introduction of a new product line, BioSpeciFx ®, further personalizing cancer treatments will help. BioSpeciFx ® consists of carefully selected sets of well validated and clinically useful biomarker tests that critical molecular targets within a patient identify cells. By using the information from BioSpeciFx ® in combination with precision sophisticated drug created response marker ChemoFx ®, doctors qualify tumor for a more complete understanding of a patient.

In combination, both products offer a supplementary amount of information to look at the doctors both enable the relevant molecular targets is as also the synergistic activity of the drug combinations on the entire cell. BioSpeciFx ® provides proteomic and genomic information, while ChemoFx ® takes into account all functional features of a tumor account not covered by biomarker tests, including a sensitivity and resistance information.

"The comprehensive precision tumor profile developed presented the most complete offer for cancer patients available today, because it integrates both genomic and proteomic information with functional profiling of ChemoFx ®," says Sean McDonald, CEO of precision Therapeutics. "We are very excited, a closer look at each patient tumor doctors offer, as we continue to develop products to personalize treatments for cancer patients."

Source: Precision Therapeutics